IL6 and neoplasm: In therapy-resistant stromal-tumor niches, IL-6/STAT3 signaling drives the expansion of BMSCs, that, in turn, secrete extracellular vesicles containing onco-miR221, able to induce hormonal therapy resistance through the generation of Notch3high/ERlow/CD133high CSCs (Sansone et al., 2017).